External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

External broker reports(aggregated public sources)

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>On 19 April 2023, Wesfarmers Limited (ASX:WES) through its subsidiary Australian Pharmaceuticals Industries Pty Ltd (API) proposed a non-binding, indicative and conditional proposal to acquire 100% of SLA for cash consideration of $3.15.</li><li>Wilson Asset Management who hold 9.3% of SLA will vote in favour of the scheme.</li><li><div><div><div><p>The Board of SLA have concluded that in the best interests of shareholders they will progress the Indicative Proposal and allow WES to undertake due diligence, and negotiation of a binding Scheme Implementation Scheme.</p></div></div></div></li><li><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></li></ul>

On 19 April 2023, Wesfarmers Limited (ASX:WES) through its subsidiary Australian Pharmaceuticals Industries Pty Ltd (API) proposed a non-binding, indicative and conditional proposal to acquire 100% of SLA for cash consideration of $3.15.Wilson Asset Management who hold 9.3% of SLA will vote in favour of the scheme.The Board of SLA have concluded that in the best interests of shareholders they will progress the Indicative Proposal and allow WES to undertake due diligence, and negotiation of a binding Scheme Implementation Scheme.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Silk Laser Australia Limited (SLA) - Offer from Wesfarmers

<ul><li>In 1H23, SLA had cash sales of $102.8m (vs TCe of $102.5m).</li><li>This is a strong result (+35% vs pcp) with early trading data provided by SLA for the first seven weeks of 2H23 February confirming continued strong trading with like for like cash sales +10% vs pcp.</li><li>SLA produced revenue and EBITDA of $50.5m and $12.5m respectively vs TC estimates of $54m and $13.75m.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

In 1H23, SLA had cash sales of $102.8m (vs TCe of $102.5m).This is a strong result (+35% vs pcp) with early trading data provided by SLA for the first seven weeks of 2H23 February confirming continued strong trading with like for like cash sales +10% vs pcp.SLA produced revenue and EBITDA of $50.5m and $12.5m respectively vs TC estimates of $54m and $13.75m.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Silk Laser Australia Limited (SLA) - 1H23 Result – Outperforming Expectations

<ul><li>SLA is the second largest provider of non-invasive medical aesthetics in Australia and New Zealand.</li><li>Acknowledging the concerns around consumer spending given the RBA’s current monetary policy tightening, we believe SLA remains attractive at both an industry and company level for the following reasons:</li><li>Less discretionary: The injectables and body service markets are considered an essential part of many women’s beauty routines, being more immune to consumer sentiment.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p><div><div></div></div>

SLA is the second largest provider of non-invasive medical aesthetics in Australia and New Zealand.Acknowledging the concerns around consumer spending given the RBA’s current monetary policy tightening, we believe SLA remains attractive at both an industry and company level for the following reasons:Less discretionary: The injectables and body service markets are considered an essential part of many women’s beauty routines, being more immune to consumer sentiment.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Silk Laser Australia (SLA) Initiation - Injectables a Strong Growth Area

Australia

Silk Laser Australia Ltd provides personal care services. The Company offers skin and hair care treatment, surgery, body sculpting, and cosmetic injection services. Silk Laser Clinics serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Silk Laser Australia (SLA AU)

Silk Laser Australia Limited (SLA) - Offer from Wesfarmers

Given WAM’s support of the offer and the Board’s willingness to progress through the due diligence process we see a successful outcome as likely at...

Taylor Collison

Silk Laser Australia Limited (SLA) - 1H23 Result – Outperforming Expectations

In 1H23, SLA had cash sales of $102.8m (vs TCe of $102.5m). This is a strong result (+35% vs pcp) with early trading data provided by SLA for the...

Taylor Collison

Silk Laser Australia (SLA) Initiation - Injectables a Strong Growth Area

The injectables and body service markets are considered an essential part of many women’s beauty routines, being more immune to consumer sentiment.

Taylor Collison

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)